Inhibrx Shares Up ~20%; Co Earlier Says INBRX-101 Shows Favorable Safety Profile In Patients With Alpha-1 Antitrypsin Deficiency; Says Study Demonstrates Potential To Achieve Normal Alpha-1 Antitrypsin Levels With Monthly Dosing
- Inhibrx, Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, today announced interim results from a Phase 1 clinical trial evaluating the safety
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 11)
12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers
Viridian Therapeutics (NASDAQ:VRDN) stock rose 22.49% to $19.17 during Tuesday's pre-market session. The company's market cap stands at $331.8 million.
Inhibrx To Host Webcast Presentation Of Interim Results From The Phase 1 Trial Of INBRX-101, Its Recombinant Human AAT-Fc Protein For The Treatment Of Alpha-1 Antitrypsin Deficiency
Inhibrx, Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, today announced that it will host a live webcast presentation on Tuesday,
JMP Securities Initiates Coverage On Inhibrx with Market Outperform Rating, Announces Price Target of $46
JMP Securities analyst Reni Benjamin initiates coverage on Inhibrx (NASDAQ:INBX) with a Market Outperform rating and announces Price Target of $46.
Inhibrx Q2 EPS $(0.55) Up From $(0.99) YoY
Inhibrx (NASDAQ:INBX) reported quarterly losses of $(0.55) per share. This is a 44.44 percent increase over losses of $(0.99) per share from the same period last year.
The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy’s Launches Generic Vascepa, Halozyme Strikes Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 21)
Inhibrx Launches Mid-Stage Bone Cancer Study With INBRX-109, Amends Loan Agreement With Oxford
Inhibrx Inc (NASDAQ:INBX) has initiated a potential registration-enabling Phase 2 study of INBRX-109 in conventional chondrosarcoma, a type of bone cancer…